Also trades as: 0950.HK (HKSE) · $vol 0M
LPCUF OTC
Lee's Pharmaceutical Holdings Limited
1W: +0.0%
1M: -2.4%
3M: -2.4%
YTD: -2.4%
1Y: -1.3%
3Y: +186105.9%
5Y: -83.6%
$0.19
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Cash Flow Trends
Operating Cash Flow
$242M
+119.8% ▲
5Y CAGR: -9.6%
Capital Expenditures
$208M
-30.0% ▼
5Y CAGR: -10.5%
Free Cash Flow
$34M
+175.1% ▲
5Y CAGR: -2.6%
Dividends Paid
$18M
-66.7% ▼
Buybacks
$0
+0.0% ▲
Net Change in Cash
$49M
+326.5% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $134M | $2.0B | $68M | $31M | $98M |
| Depreciation & Amort. | $128M | $147M | $152M | $150M | $148M |
| Stock-Based Comp. | $17M | $17M | $12M | $793K | $406K |
| Change in Working Capital | -$71M | $65M | -$15M | -$78M | -$51M |
| Other Non-Cash Items | -$4M | -$2M | $66M | $7M | $47M |
| Operating Cash Flow | $219M | $211M | $284M | $110M | $242M |
| — Investing Activities — | |||||
| Capital Expenditures | -$358M | -$371M | -$214M | -$29M | -$44M |
| Acquisitions (Net) | -$166M | -$4M | $880K | -$620K | $0 |
| Investment Purchases | -$20M | -$28M | -$46M | -$6M | -$9M |
| Investment Sales | $45M | -$327M | -$880K | $0 | $0 |
| Other Investing | -$25M | $360M | $3M | -$109M | -$138M |
| Investing Cash Flow | -$524M | -$370M | -$256M | -$145M | -$190M |
| — Financing Activities — | |||||
| Net Debt Issuance | $7M | $105M | -$92M | $35M | $26M |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | -$38M | -$36M | -$24M | -$11M | -$18M |
| Other Financing | $21M | -$11M | -$13M | -$11M | -$10M |
| Financing Cash Flow | -$10M | $61M | -$129M | $13M | -$2M |
| Net Change in Cash | -$318M | -$98M | -$88M | -$22M | $49M |
| Cash End of Period | $375M | $278M | $189M | $168M | $217M |
| Free Cash Flow | -$139M | -$160M | $70M | -$46M | $34M |